Cargando…

A pragmatic study of mid‐mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real‐world experience

BACKGROUND: Chinese guidelines for the treatment of type 2 diabetes (T2D) recommend basal or premixed insulins as insulin starters after failed oral antihyperglycaemic medication (OAM). This pragmatic study compared effectiveness and safety of add‐on basal insulin analog (BI) and mid‐mixture insulin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaomei, Ma, Yujin, Chen, Hong, Lou, Ying, Ji, Linong, Chen, Lulu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384022/ https://www.ncbi.nlm.nih.gov/pubmed/32267071 http://dx.doi.org/10.1111/dom.14052

Ejemplares similares

A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience
por: Zeng, Tianshu, et al.
Publicado: (2021)

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
por: Jain, S M, et al.
Publicado: (2010)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China
por: Chen, Minyuan, et al.
Publicado: (2022)

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia
por: TSAI, Shih-Tzer, et al.
Publicado: (2011)

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
por: Bonafede, Machaon MK, et al.
Publicado: (2010)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
por: Yki‐Järvinen, H., et al.
Publicado: (2015)

Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus
por: Zhang, Puhong, et al.
Publicado: (2020)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan, Wing Bun, et al.
Publicado: (2017)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
por: Kim, Ji-Hyun, et al.
Publicado: (2015)

Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin
por: Buysman, Erin K., et al.
Publicado: (2018)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open‐label, randomized controlled BEYOND‐V trial
por: Pan, Qi, et al.
Publicado: (2022)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
por: Terauchi, Y., et al.
Publicado: (2016)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study
por: Velojic-Golubovic, Milena, et al.
Publicado: (2021)

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
por: Arakaki, R F, et al.
Publicado: (2014)

SUN-186 Insulin Antibody Associated Severe Insulin Resistance Leading to Uncontrolled Hyperglycemia
por: Amir, Hajira, et al.
Publicado: (2019)

Insulin Injection Technique in China Compared with the Rest of the World
por: Song, Zhenqiang, et al.
Publicado: (2018)

Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
por: Niezen, Sebastian, et al.
Publicado: (2019)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Achieving Effective and Efficient Basal Insulin Optimal Management by Using Mobile Health Application (APP) for Type 2 Diabetes Patients in China
por: Cai, Xiaoling, et al.
Publicado: (2020)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Future of newer basal insulin
por: Madhu, S. V., et al.
Publicado: (2013)

Cardiovascular effects of basal insulins
por: Mannucci, Edoardo, et al.
Publicado: (2015)

Basal insulin titration by the app
por: Vangoitsenhoven, Roman, et al.
Publicado: (2023)

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
por: Meneghini, Luigi F., et al.
Publicado: (2019)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Leptin Deficiency Causes Insulin Resistance Induced by Uncontrolled Diabetes
por: German, Jonathan P., et al.
Publicado: (2010)

Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study
por: Sethi, Bipin, et al.
Publicado: (2022)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_002co53g6u50afcgvmp00rtrfq